Table 1. EGPA diagnostic disease characteristics of patients.
| Patient type of disease | Asthma/eosinophil (% max value) | Biopsy evidence | PNS | Nonfixed lung infiltrates | CRSwNP | Heart | Kidney | Palpable purpura | Alveolar hemorrhage | ANCA status | Disease duration (yr) | Immuno suppressive therapy since diagnosis | OCS dose (mg/day)* | Other |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | + (17) | − | + | + | + | − | − | − | − | + | 20 | CyA | 5 | Arth |
| 2 | + (11) | − | − | + | + | − | − | − | − | + | 4 | MTX | 5 | Arth |
| 3 | + (16) | − | + | + | + | − | − | − | − | − | 29 | No | 5 | - |
| 4 | + (13) | + | − | − | + | − | − | − | − | − | 8 | No | 7.5 | - |
| 5 | + (15) | − | − | + | + | − | − | + | − | − | 15 | CyA/IFX | 5 | - |
| 6 | + (61) | − | + | + | + | − | + | + | − | + | 21 | CyA/CKF/IFX | 15 | - |
| 7 | + (25) | + | − | + | + | − | − | + | − | − | 22 | CyA | 5 | GI/Arth |
| 8 | + (36) | − | + | + | + | − | + | + | − | + | 3 | CyA/AZA/RTX | 5 | - |
| 9 | + (31) | + | − | + | + | − | + | + | − | + | 4 | AZA/CyA | 10 | - |
| 10 | + (17) | − | − | + | + | − | − | − | − | + | 13 | CyA/MTX | 20 | - |
| 11 | + (30) | − | − | + | + | − | − | − | − | − | 12 | CyA | 15 | - |
| 12 | + (12) | + | − | + | + | + | − | + | − | − | 27 | No | 5 | Sierositis |
| 13 | + (13) | − | − | + | + | − | − | + | − | − | 32 | CyA/IFX | 5 | - |
| 14 | + (31) | − | + | − | + | − | − | − | − | + | 9 | OMA | 7.5 | - |
| 15 | + (26) | + | − | + | + | − | − | − | − | − | 26 | CyA/AZA | 5 | - |
| 16 | + (36) | + | − | + | + | + | + | − | − | − | 6 | MTX/IFX | 12.5 | - |
| 17 | + (19) | + | + | + | + | − | − | − | − | + | 6 | MMF | 7.5 | GI |
| 18 | + (12) | + | − | + | + | − | + | − | − | − | 7 | CyA | 7.5 | - |
PNS, peripheral nervous system; CRSwNP, chronic rhinosinusitis with nasal polyps; ANCA, anti-neutrophil cytoplasmic antibodies; OCS, oral corticosteroids; CyA, cyclosporine A; MTX, methotrexate; IFX, infliximab; CKF, cyclophosphamide; AZA, azathioprine; RTX, rituximab; OMA, omalizumab; MMF, mycophenolate mofetil; Arth = arthritis; GI = gastrointestinal.
*At beginning of mepolizumab.